Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics, Inc. (NYSE American: CATX) is a radiopharmaceutical development company focused on 212Pb-based theranostic treatments and imaging for cancer. The CATX news page on Stock Titan aggregates company announcements, clinical data updates, conference presentations, financial disclosures, and other material events drawn from press releases and SEC filings.
According to recent communications, Perspective regularly reports interim results from its Phase 1/2a trials of [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, VMT01 in melanoma patients with MC1R-positive imaging scans, and PSV359 in FAP-α-positive solid tumors. News items often summarize safety findings, investigator-assessed anti-tumor activity, and progress across dose cohorts, along with plans for data presentations at major meetings such as ASCO, ASCO-GI, ESMO, NANETS, and AACR-NCI-EORTC conferences.
Investors and observers can also find updates on corporate presentations, participation in healthcare and biopharma conferences, and periodic business highlights tied to quarterly financial results. Form 8-K filings referenced in the news flow include earnings releases, updated corporate slide decks, and information about executive appointments and employment agreements.
For anyone tracking CATX, this news feed provides a centralized view of Perspective’s clinical development trajectory, manufacturing expansion efforts around its proprietary 212Pb generator, and key corporate developments. Users interested in radiopharmaceutical and oncology catalysts may wish to revisit this page around major medical congresses, scheduled earnings dates, and company-announced business updates.
Perspective Therapeutics (NYSE AMERICAN: CATX) said senior leadership will participate in investor events in April 2026. Key appearances include a presentation and fireside chat at the Needham Virtual Healthcare Conference on April 14, 2026 (9:30–10:10 a.m. ET) and one-on-one meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston.
Management will be available for investor 1x1 meetings; times and virtual access details follow each conference schedule.
Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated data for its [212Pb]VMT-α-NET program were accepted as a poster presentation at the AACR Annual Meeting 2026 in San Diego, April 17–22, 2026.
The poster, by Thorvardur Halfdanarson from Mayo Clinic, reports safety and preliminary efficacy from dose‑finding cohorts 1–3 in advanced SSTR2+ neuroendocrine tumors and is scheduled for April 20, 2026, 9:00 am–12:00 pm, Abstract CT088.
Perspective Therapeutics (NYSE AMERICAN: CATX) reported full year 2025 results and a business update on March 16, 2026. Key clinical updates: VMT-α-NET shows favorable tolerability, no DLTs across dose levels, and 76% of 25 efficacy-evaluable patients were progression-free at updated follow-up.
Financials: cash and short-term investments of ~$145M as of December 31, 2025, plus ~$164M net proceeds from a February 2026 equity offering, expected to fund operations into late 2027. 2025 net loss was $103.1M; R&D expense rose ~102% to $84.2M.
Perspective Therapeutics (NYSE AMERICAN: CATX) will report full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The company said the results and update will be posted on its newsroom press releases page.
Investors can expect a webcast or press release posting following the market close on that date.
Perspective Therapeutics (NYSE AMERICAN: CATX) priced an underwritten offering to raise approximately $175 million of gross proceeds by selling 39,576,088 common shares at $3.79 per share and pre-funded warrants to purchase 6,598,046 shares at $3.789 each. The offering is expected to close on or about February 3, 2026, subject to customary closing conditions.
Perspective said it will use net proceeds to advance clinical development, invest in manufacturing facilities, and for working capital and general corporate purposes; a portion may be used for acquisitions or licenses though no commitments exist.
Perspective Therapeutics (NYSE AMERICAN: CATX) provided clinical and operational updates ahead of its J.P. Morgan presentation on January 14, 2026 at 2:15 p.m. PT. Key points: updated [212Pb]VMT-α-NET data (DCO Dec 10, 2025) show no DLTs in a 56-patient safety set and durable disease control in an efficacy subset (19/25 without progression). Cohort 3 DLT assessment is complete and enrollment continues. VMT01 and PSV359 remain in early dose-finding stages with additional clinical readouts expected mid–late 2026. Manufacturing capacity expansion is underway.
Perspective Therapeutics (NYSE:CATX) reported updated interim Phase 1/2a data for [212Pb]VMT-α-NET with a data cut-off of December 10, 2025. Safety analysis covered 56 patients across three dose cohorts (2.5, 5.0, 6.0 mCi) with no DLTs, no treatment-related discontinuations, and no Grade 5 events; Grade ≥3 events occurred in 21 patients (37.5%) and one transient Grade 4 lymphopenia resolved. Efficacy analysis in 25 patients (2 in Cohort 1; 23 in Cohort 2) showed 9/23 (39%) objective responses in Cohort 2 (8 confirmed previously) and 19/25 (76%) without progression and alive at update. Cohort 3 DLT assessment completed and additional enrollment cleared.
Perspective Therapeutics (NYSE American: CATX) announced that CEO Thijs Spoor will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026.
The company presentation is scheduled for 2:15–2:55 p.m. PT at The Westin St. Francis Hotel and will cover Perspective's radiopharmaceutical development programs targeting cancers throughout the body.
Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated data for its [212Pb]VMT-α-NET program were accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) Congress 2026.
The accepted poster, presented by Thorvardur Halfdanarson from Mayo Clinic Comprehensive Cancer Center, covers safety and preliminary efficacy results in advanced SSTR2-expressing neuroendocrine tumors. The poster is Abstract No. 635 in the session "Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract" and will be shown on January 9, 2026 at two times: 11:30 am–1:00 pm PT and 5:00–6:00 pm PT. ASCO-GI will release full regular-abstract details on January 5, 2026.
Perspective Therapeutics (NYSE AMERICAN: CATX) said senior leadership will participate in two investor conferences in early December 2025.
Events: Piper Sandler 37th Annual Healthcare Conference fireside chat on Dec 2, 2025 at 1:00–1:25 p.m. ET in New York, and Evercore 8th Annual Healthcare Conference fireside chat on Dec 3, 2025 at 3:00–3:20 p.m. ET in Miami. Management will also be available for one-on-one investor meetings.